Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tolerx, GlaxoSmithKline deal

Tolerx and GSK partnered to develop and commercialize Tolerx's otelixizumab (formerly TRX4). Tolerx will be responsible

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE